Comparing the current results to its competitors, Mustang Bio Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 16.02 %, recorded in the same quarter.
Mustang Bio inc , slower than the average decrease reported by the company's competitors of -9.33 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -9.33 %
Mustang Bio Inc 's Comment on Competition and Industry Peers
The pharmaceutical and biotechnology industries are highly competitive, with competitors including pharmaceutical companies, biotechnology firms, universities, and public and private research institutions. Many competitors possess greater capital resources, larger research and development teams and facilities, and more extensive experience in drug development, regulation, manufacturing, and marketing. These organizations also compete to recruit qualified personnel, secure partners for joint ventures or collaborations, and license competitive technologies. Success requires identifying novel drugs or treatment methods and completing their development ahead of competitors. Additionally, drugs under development must compete with existing therapies.
June 17, 2024
Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy
Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 monthsIn a groundbreaking development, Mustang Bio, a clinical-stage biopharmaceutical company, has released promising results from their Phase 1/2 clinical trial evaluating the efficacy and safety of MB-106, a CD20-targeted autologous CAR-T therapy, in patients with Waldenstrom Macroglobulinemia (WM). The latest data demonstrates an impressive overall response rate of 90% within the treated c...
March 7, 2024
Mustang Bio, a clinical-stage biopharmaceutical company focused on developing innovative gene therapies for cancer, recently announced the publication of promising data from a Phase 1 clinical trial evaluating their investigational therapy, MB-101 IL13R2-targeted CAR T-cells, in patients with high-grade glioma. The findings were published in the prestigious scientific journal Nature Medicine, highlighting the potential of this therapy in treating this aggressive form of brain cancer.Glioma is a type of tumor that arises from glial cells in the brain or spinal cord. High-grade glioma, in particular, is an aggressive and difficult-to-treat type of cancer with limited treatment options. Therefore, the results f...
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Sources:
Mustang Bio inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Mustang Bio inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
